To validate the increased expression of MIOX in PRAD samples compared with normal prostate tissues using immunohistochemistry staining analysis (Figure 6C), we first collected samples and explored the prognostic implications of MIOX expression in 81 PRAD patients undergoing first-line AR signaling inhibitor from the Renji cohort. Here, AR is linked to prostate adenocarcinoma.